Our aim was to identify an optimal theranosticpair that could be studied in the future for tumor imaging and α-particleRIT of HER2-positive BC to improve patient outcome, particularly withthe emergence of resistance to current standard-of-care therapies. This evidence concerns the gene ERBB2 and breast cancer.